Pfizer, Inc. (NYSE:PFE) was upgraded by equities researchers at Vetr from a “hold” rating to a “buy” rating in a report issued on Thursday. The firm currently has a $38.82 price objective on the biopharmaceutical company’s stock. Vetr‘s price objective points to a potential upside of 9.38% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Berenberg Bank set a $39.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Tuesday, October 3rd. Cowen Inc set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. Finally, BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the stock. Pfizer has a consensus rating of “Buy” and a consensus price target of $38.66.

Shares of Pfizer (NYSE PFE) opened at $35.49 on Thursday. Pfizer has a 12 month low of $30.51 and a 12 month high of $36.78. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The firm has a market cap of $211,217.66, a PE ratio of 14.17, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the previous year, the company earned $0.61 EPS. The business’s revenue was up .9% on a year-over-year basis. equities analysts expect that Pfizer will post 2.6 earnings per share for the current fiscal year.

In related news, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the sale, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now directly owns 132,124 shares in the company, valued at $4,492,216. The disclosure for this sale can be found here. Insiders sold a total of 366,557 shares of company stock valued at $12,532,406 over the last 90 days. Corporate insiders own 0.06% of the company’s stock.

Several institutional investors have recently made changes to their positions in PFE. Shine Investment Advisory Services Inc. bought a new stake in Pfizer during the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new stake in Pfizer during the 2nd quarter worth approximately $103,000. D. Scott Neal Inc. grew its holdings in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new stake in Pfizer during the 1st quarter worth approximately $121,000. Finally, Herndon Capital Management LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $120,000. 69.34% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/pfizer-inc-pfe-stock-rating-upgraded-by-vetr-inc/1724848.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.